Clearance Summary
allay Nerve Cap received FDA 510(k) clearance under submission number DEN230061, sponsored by Tulavi Therapeutics. The device was reviewed via the Direct premarket notification pathway and assigned to the Neurology review panel. The statutory decision date of record is 2024-07-16.
- Submission: DEN230061
- Applicant / Sponsor: Tulavi Therapeutics
- Clearance pathway: Direct
- Review panel: Neurology
- Device class: Class II
- Regulation citation: 21 CFR 882.5260
- Decision date: 2024-07-16
Classification & Regulation
This clearance is catalogued under FDA product code SBG and 21 CFR 882.5260, within the Neurology review panel as a Class II device.